» Articles » PMID: 36607281

Dynamic Regulation of RAS and RAS Signaling

Overview
Journal Biochem J
Specialty Biochemistry
Date 2023 Jan 6
PMID 36607281
Authors
Affiliations
Soon will be listed here.
Abstract

RAS proteins regulate most aspects of cellular physiology. They are mutated in 30% of human cancers and 4% of developmental disorders termed Rasopathies. They cycle between active GTP-bound and inactive GDP-bound states. When active, they can interact with a wide range of effectors that control fundamental biochemical and biological processes. Emerging evidence suggests that RAS proteins are not simple on/off switches but sophisticated information processing devices that compute cell fate decisions by integrating external and internal cues. A critical component of this compute function is the dynamic regulation of RAS activation and downstream signaling that allows RAS to produce a rich and nuanced spectrum of biological outputs. We discuss recent findings how the dynamics of RAS and its downstream signaling is regulated. Starting from the structural and biochemical properties of wild-type and mutant RAS proteins and their activation cycle, we examine higher molecular assemblies, effector interactions and downstream signaling outputs, all under the aspect of dynamic regulation. We also consider how computational and mathematical modeling approaches contribute to analyze and understand the pleiotropic functions of RAS in health and disease.

Citing Articles

Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective.

Prajapati V, Singh A, Kumar A, Singh H, Pathak P, Grishina M RSC Med Chem. 2025; .

PMID: 40052089 PMC: 11880839. DOI: 10.1039/d4md00923a.


Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1.

Leguay K, Kent O Onco Targets Ther. 2025; 18:147-159.

PMID: 39882405 PMC: 11776410. DOI: 10.2147/OTT.S496228.


Allosteric modulation of NF1 GAP: Differential distributions of catalytically competent populations in loss-of-function and gain-of-function mutants.

Xu L, Jang H, Nussinov R Protein Sci. 2025; 34(2):e70042.

PMID: 39840811 PMC: 11751910. DOI: 10.1002/pro.70042.


Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells.

Yang L, Du Z, Peng Y, Zhang W, Feng W, Yuan Y Korean J Physiol Pharmacol. 2024; 29(1):67-81.

PMID: 39539176 PMC: 11694007. DOI: 10.4196/kjpp.24.176.


Ras, RhoA, and vascular pharmacology in neurodevelopment and aging.

Nussinov R, Jang H, Cheng F Neurochem Int. 2024; 181:105883.

PMID: 39427854 PMC: 11614691. DOI: 10.1016/j.neuint.2024.105883.


References
1.
Bugaj L, Sabnis A, Mitchell A, Garbarino J, Toettcher J, Bivona T . Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science. 2018; 361(6405). PMC: 6430110. DOI: 10.1126/science.aao3048. View

2.
Su W, Mukherjee R, Yaeger R, Son J, Xu J, Na N . ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Mol Cell. 2022; 82(13):2443-2457.e7. PMC: 9271631. DOI: 10.1016/j.molcel.2022.04.034. View

3.
Castel P, Dharmaiah S, Sale M, Messing S, Rizzuto G, Cuevas-Navarro A . RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity. Proc Natl Acad Sci U S A. 2021; 118(33). PMC: 8379911. DOI: 10.1073/pnas.2103261118. View

4.
Markevich N, Moehren G, Demin O, Kiyatkin A, Hoek J, Kholodenko B . Signal processing at the Ras circuit: what shapes Ras activation patterns?. Syst Biol (Stevenage). 2006; 1(1):104-13. DOI: 10.1049/sb:20045003. View

5.
Prior I . Ras Variant Biology and Contributions to Human Disease. Methods Mol Biol. 2021; 2262:3-18. DOI: 10.1007/978-1-0716-1190-6_1. View